UroGen raises $120M from institutions; UGN-102 Phase 3 trials meet endpoints

UroGen Pharma Ltd.

$120M gross proceeds from private placement at $9.54/share led by RA Capital and Great Point Partners.
ATLAS trial: UGN-102 reduced risk of recurrence/progression/death by 55% vs TURBT alone.
ENVISION trial: 79.2% complete response rate at 3 months for UGN-102.
Pre-funded warrants at $0.001/share, not expiring; closing expected July 28.
NDA submission for UGN-102 anticipated in 2024 pending additional data.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

UroGen Pharma Ltd. entered into Securities Purchase Agreement with certain institutional and other accredited investors valued at $120.0 million (effective 2023-07-26).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional and other accredited investors
Value: $120.0 million
Effective: 2023-07-26

Exact text from the filing

On July 26, 2023, UroGen Pharma Ltd., an Israeli company (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and other accredited investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers 12,579,156 ordinary shares of the Company (“Shares”) (or in lieu of Shares, pre-funded warrants to purchase ordinary shares of the Company) at a purchase price of $9.54 per Share (or $9.539 for each ordinary share underlying a pre-funded warrant), in a private placement transaction (the “Private Placement”).

View on SEC.gov

Browse all material agreements →

UroGen Pharma Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-23-195560

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.